A propranolol-glucagon test was evaluated in 24 control normal children, 21 pituitary dwarfs, 15 patients with constitutional short stature, 2 with chromosome aberration and 4 with miscellaneous diseases. The dose of glucagon enough for the stimulation of human growth hormone (HGH) secretion is more than 20 \g=m\/kg of body weight. During the test in the control subjects the serum HGH level increased from 2.3 \m=+-\1.2 ng/ml to a maximum level of 30.0 \m=+-\15.1 ng/ml, when 10 mg propranolol, regardless of body weight and 30 \ g=m\ gglucagon per kg of body weight are given. The dose of propranolol administered ranged from 0.2 to 1.0 mg/kg of body weight in normal children studied. Serum 11-OHCS also increased significantly from 14.5 \m=+-\ 11.2 \g=m\g/100 ml to 30.1 \m=+-\15.5 \g=m\g/100ml (P <0.01). There was no difference in the maximum level of urinary total catecholamines in propranolol-glucagon test between 7 pituitary dwarfs and 7 control subjects. The mechanism of HGH response to propranolol-glucagon administration is unknown, but propranolol-glucagon administration is a sensitive and reliable provocative test for HGH secretion, since false negative responses of HGH are not observed in patients with non-pituitary disease.
It has been widely accepted that the propranolol-glucagon test (P-G test) is useful for the evaluation of human growth hormone (HGH) secretion (Mitchell et al. 1971; Parks et al. 1973 ). This provocative test has a merit that the proce¬ dure is simpler than that of insulin-induced hypoglycaemia (ITT) and arginine infusion (A test), since propranolol can be administered orally and glucagon is given intramuscularly or subcutaneously. However, precise evaluation of this test has not been previously reported. This paper describes endocrinological change during the test in normal subjects and in patients with abnormal stature.
SUBJECTS AND METHODS

Subjects
Twenty-one cases of pituitary dwarf aged from 7 to 25 years were studied. Diagnostic criteria are as follows: 1) well-proportioned dwarf, height is less than -3.0 sd, 2) height increase is less than 12 cm per 3 years when the patients are over 6 years, 3) ratio of bone age to chronological age is less than 0.75, 4) the maximum HGH level in responses to both ITT and A test is less than 5 ng/ml. In this series, patients with short stature, who had no response to the above mentioned two provocative tests but significant or normal response to P-G test were excluded from the group of pituitary dwarfs. Twenty-four normal subjects and 15 non-pituitary dwarfs aged from 4 to 18 years were also studied as control subjects. Patients (37.5 ± 6 .6 ng/ml) was signifi¬ cantly (P < 0.05) higher than that following glucagon administration only (22.9 ± 16.9 ng/ml).
The increase of serum 11-OHCS ranged from 3.0 to 10.5 tig/100 ml (7.4 ± 2.9) in the glucagon test and from 15.0 to 30 (20.5 ± 6.8) ,ug/100 ml in P-G test. The latter was significantly (<P«<0.01) higher than the former.
2) Effect of dose of glucagon on HGH secretion (Experiment 2)
In order to determine an appropriate dose of glucagon for stimulating HGH secretion, 5 normal children were given glucagon at the dose of 10, 20, and 30 tig per kg of body weight at interval of 2 days and simultaneously given 10 mg of propranolol regardless of the body weight. Fig. 1 (Fig. 2) . Hence, HGH response to P-G test was considered to be normal when the maximum level of HGH was more than 10 ng/ml. The serum cortisol increased from 14.5 ± 11.2 /ug/100 ml to 30.1 ± 15.5 jugllOO ml at 180 min (P <0.0l), and its increment was 20.3 ± 6.4 jug/lQQ ml. In 12 pituitary dwarfs, HGH levels before and at 90, 120, 180 min after the test were 1.6 ± 0.31, 2.2 ± 1.32, 1.8 ± 1.41, 1.8 ± 0.92 ng/ml, respectively. The maximum levels were all less than 3.8 ng/ml. Although 10 mg of propranolol was given to each subject regardless of body weight, this dose was in the range of 0.2 to 1.0 mg per kg of body weight as observed in those control subjects who showed normal HGH response to P-G test.
The blood glucose levels of control and patients were 82.0 ± 10.0; 137.5 ± 25.5 and 75.6 ± 14.1 mg/100 ml at 0, 30 and 150 min, respectively, while those of pituitary dwarfs were 79.7 ± 12.4, 127.6 ± 17.6 and 66.2 ± 17.6 mg/100 ml at 0, 30 and 150 min, respectively. There was no significant correlation between the maximum HGH levels and the changes in the falling blood glucose levels in the control subjects. 4) Catecholamine levels in propranolol-glucagon test (Experiment 4) Urinary catecholamines were assayed for the specimen obtained in -2~0, 0~+2, and +2~4 h of the PG test in 7 control subjects and 7 pituitary dwarfs who showed a normal response of urinary 17-OHCS to SU 4885 as mentioned belore. Total urinary catecholamines increased significantly from 1.69 ± 1.10 to the maximum level of 4.39 ± 2.59 ptg/2 h (P <C 0.05) in control subjects, and 2.15 ± 1.09 to 6.55 ± 3.03 fig/ml in pituitary dwarfs (P < 0.025) as shown in Table 2 . There was no significant difference, however, in the maximum levels between pituitary dwarfs and control subjects.
5) Comparison of P-G test with other provocative tests (Experiment 5)
The HGH secretion in the ITT and the A test is functionally impaired in patients with hypogonadism (Hashimoto et al. 1971 ) and in prepubertal normal subjects (Parker et al. 1967) and it returns to normal when treated with sex hormones. The P-G test is a sensitive and reliable provocative test for HGH secretion since the HGH secretion in some patients with miscellaneous diseases showed no or sub-normal response to other tests though normal to P-G. It is natural, however, that the normal HGH secretion in response to P-G test does not always mean that there is a normal HGH secretion in response to the physiological stimuli of daily life.
